ArticleJGH open : an open access journal of gastroenterology and hepatology2019
The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching.Scientific reports · 2025Article
- A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation.Journal of gastroenterology · 2022Review
- Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimTacrolimus (TAC) is an important therapeutic option for remission induction in patients with refractory ulcerative colitis (UC). However, there is little evidence available on long-term outcomes and maintenance treatments after TAC therapy, especially in cases with previous tumor necrosis factor-α (TNF-α) inhibitor therapy.
methodsLong-term outcomes and remission induction after TAC treatment were retrospectively examined in refractory UC patients with and without previous TNF-α inhibitor therapy.
resultsThe mean disease activity index and the endoscopic activity index scores decreased significantly during the 12-week treatment after TAC therapy in both groups, showing a significantly greater decrease in the group without TNF-α inhibitor therapy than in the group with previous TNF-α inhibitor therapy. One year or more after TAC therapy, TNF-α inhibitor and/or azathioprine was used as maintenance therapy in most cases in the group without previous TNF-α inhibitor treatment, while azathioprine was primarily used in the group with previous TNF-α inhibitor treatment. Colectomy was performed in 45.5% (5/11) and 15.6% (7/45) of the groups with and without previous TNF-α inhibitor therapy, respectively, and the group without previous TNF-α inhibitor treatment had a better colectomy-free rate than the group with previous TNF-α inhibitor treatment after TAC therapy on Kaplan-Meier analysis.
conclusionsTAC is effective for remission induction in refractory UC patients with and without previous TNF-α inhibitor treatment. Maintenance medication after TAC therapy is an issue for the future, especially in UC cases with previous TNF-α inhibitor treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.